OPTI-AML Venetoclax Optimization

Summary Blood Cancer United announced more than 50 ASCO and EHA 2026 abstracts, highlighted by an oral EHA presentation from the randomized Phase 2 OPTI-AML substudy evaluating reduced-duration venetoclax dosing with azacitidine in newly diagnosed AML patients aged 60 and older. What Happened The OPTI-AML…